Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBMP-2/CPM in Closed Diaphyseal Tibial Fracture
NCT00387686Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2006
- Primary completion
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of dibotermin alfa in tibial fracture (4 arms), sponsored by Pfizer. Primary endpoints: Time to fracture union and Time to return to normal function. Started Nov 2006; status: terminated.
02
Drugs
dibotermin alfa
03
Conditions
tibial fracture
Beyond the preview
Go deeper on NCT00387686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387686.